AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11856686 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (loading dose via intraarterial injection or IV)
Number of subjects: 17
Study 11856686 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (intraarterial loading dose)
Number of subjects: 17
Study 11856686 — intervention group
Group type: COMPARATOR
Intervention: Control (rt-PA and heparin only)
Number of subjects: 17
Study 10192826 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (29 micrograms/kg)
Number of subjects: 0
Study 10192826 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.5 micrograms/kg)
Number of subjects: 0
Study 10192826 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (2 micrograms/kg)
Number of subjects: 0
Study 10192826 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 0
Study 10192826 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (7 micrograms/kg)
Number of subjects: 0
Study 10192826 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 0
Study 7478776 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg aerosolized furosemide
Number of subjects: 48
Study 7478776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2303573 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% potassium nitrate glycerine-based gel
Number of subjects: 12
Study 2303573 — intervention group
Group type: EXPERIMENTAL
Intervention: glycerine gel without potassium nitrate
Number of subjects: 12
Study 2303573 — intervention group
Group type: COMPARATOR
Intervention: no gel and no treatment (control)
Number of subjects: 12
Study 6995134 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 15 mg t.i.d.
Number of subjects: 8
Study 6995134 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg t.i.d.
Number of subjects: 8
Study 6995134 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 35 mg t.i.d.
Number of subjects: 8
Study 6995134 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment periods
Number of subjects: 8
Study 31543072 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational animations
Number of subjects: 1194
Study 31543072 — intervention group
Group type: COMPARATOR
Intervention: Brochures with visuals
Number of subjects: 1194
Study 31543072 — intervention group
Group type: COMPARATOR
Intervention: Brochures without visuals
Number of subjects: 1194
Study 31543072 — intervention group
Group type: COMPARATOR
Intervention: Materials currently used by the NIH
Number of subjects: 1194
Study 28490871 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (Noninvasive Positive Pressure Ventilation) for 3 months
Number of subjects: 115
Study 28490871 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimized treatment)
Number of subjects: 115
Study 26228884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular rtPA treatment
Number of subjects: 64
Study 26228884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rtPA treatment)
Number of subjects: 64
Study 23809500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Program for Infertility (MBPI)
Number of subjects: 55
Study 23809500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 22794269 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnesics with MTL damage including the perirhinal cortex
Number of subjects: 0
Study 22794269 — intervention group
Group type: COMPARATOR
Intervention: Controlled interference
Number of subjects: 0
Study 22794269 — intervention group
Group type: COMPARATOR
Intervention: Amnesics with damage limited to the hippocampus
Number of subjects: 0
Study 19440955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered propofol-alfentanil sedation (NAPS)
Number of subjects: 178
Study 19440955 — intervention group
Group type: COMPARATOR
Intervention: Opioid-benzodiazepine sedation (DPS)
Number of subjects: 178
Study 19126940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sildenafil for 12 weeks
Number of subjects: 12
Study 15679006 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 23
Study 15679006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12000004 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol Turbohaler 12 microg b.i.d.
Number of subjects: 145
Study 12000004 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol Accuhaler 50 microg b.i.d.
Number of subjects: 145
Study 10216323 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of intravenous methylprednisolone
Number of subjects: 56
Study 10216323 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 56
Study 7793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 500 mg twice daily for 20 days
Number of subjects: 232
Study 7793869 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline, 100 mg three times daily for 20 days
Number of subjects: 232
Study 7793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 232
Study 7793869 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 232
Study 7793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 232
Study 1699982 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg twice daily)
Number of subjects: 8
Study 68044 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous ragweed extract (mean cumulative dose of 11.7 microng antigen E, equivalent to 4,180 PNU)
Number of subjects: 39
Study 68044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 68044 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous ragweed extract (mean dose of 31.2 microng antigen E, equivalent to 11,140 PNU)
Number of subjects: 39
Study 30523765 — intervention group
Group type: EXPERIMENTAL
Intervention: Selu-metinib in combination with dacarbazine
Number of subjects: 0
Study 30523765 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine alone
Number of subjects: 0
Study 26970181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose moderate-intensity aerobic exercise (150 min·week(‐1))
Number of subjects: 39
Study 26970181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose moderate-intensity aerobic exercise (300 min·week(‐1))
Number of subjects: 39
Study 26970181 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 39
Study 23716039 — intervention group
Group type: EXPERIMENTAL
Intervention: Five or more portions of FV per day for 16 weeks
Number of subjects: 83
Study 23716039 — intervention group
Group type: COMPARATOR
Intervention: Two portions of FV per day for 16 weeks (Control)
Number of subjects: 83
Study 21953877 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-stiffness shoes
Number of subjects: 79
Study 21953877 — intervention group
Group type: COMPARATOR
Intervention: Constant-stiffness shoes
Number of subjects: 79
Study 20184577 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-369,003 100 mg modified release (MR)
Number of subjects: 418
Study 20184577 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-369,003 40 mg immediate release (IR)
Number of subjects: 418
Study 20184577 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-369,003 100 mg MR
Number of subjects: 418
Study 20184577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 17578979 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg preoperatively and 200 mg every 12 h postoperatively
Number of subjects: 200
Study 17578979 — intervention group
Group type: COMPARATOR
Intervention: Placebo preoperatively and matching placebo every 12 h postoperatively
Number of subjects: 200
Study 15455468 — intervention group
Group type: EXPERIMENTAL
Intervention: aSAH patients
Number of subjects: 16
Study 11890384 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine, body therapy (somatic therapy, bodywork), and guided imagery for 6 months
Number of subjects: 37
Study 11890384 — intervention group
Group type: COMPARATOR
Intervention: Standard medical approaches (control group)
Number of subjects: 37
Study 11890384 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine, body therapy, and guided imagery
Number of subjects: 37
Study 9567734 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control treatment and withdrawal program (medicated participants)
Number of subjects: 41
Study 9567734 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control treatment (nonmedicated participants)
Number of subjects: 41
Study 9567734 — intervention group
Group type: COMPARATOR
Intervention: Control group (medicated participants)
Number of subjects: 41
Study 9567734 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (nonmedicated participants)
Number of subjects: 41
Study 9567734 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus control treatment (medicated participants)
Number of subjects: 41
Study 7608644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 588
Study 7608644 — intervention group
Group type: COMPARATOR
Intervention: Intra-uterine device, condom, progestogen-only pill (alternative birth-control methods)
Number of subjects: 588
Study 2240632 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia including nitrous oxide (N2O) (50%-60%) during regional anesthesia supplemented with isoflurane and intravenous adjuvants
Number of subjects: 100
Study 2240632 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia excluding nitrous oxide (N2O) during regional anesthesia supplemented with isoflurane and intravenous adjuvants
Number of subjects: 100
Study 747947 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed node dissection
Number of subjects: 140
Study 747947 — intervention group
Group type: COMPARATOR
Intervention: Immediate dissection
Number of subjects: 140
Study 31677820 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-Paclitaxel-Bevacizumab
Number of subjects: 108
Study 31677820 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-Paclitaxel
Number of subjects: 108
Study 28851171 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a (0.1 mg subcutaneous injection)
Number of subjects: 40
Study 28851171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline 2 ml subcutaneous injection)
Number of subjects: 40
Study 25481036 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17648
Number of subjects: 0
Study 25481036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23578980 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg once-daily
Number of subjects: 29
Study 23578980 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol nebulizer 1250 μg three times a day
Number of subjects: 29
Study 22053981 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR of 30:2
Number of subjects: 40
Study 22053981 — intervention group
Group type: COMPARATOR
Intervention: CVR of 15:2
Number of subjects: 40
Study 18650630 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (n = 53)
Number of subjects: 205
Study 18650630 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulating enteral nutrition (n = 52)
Number of subjects: 205
Study 18650630 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (n = 49)
Number of subjects: 205
Study 18650630 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulating parenteral nutrition (n = 51)
Number of subjects: 205
Study 17312651 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler with accessory device (MDI/AD)
Number of subjects: 150
Study 17312651 — intervention group
Group type: COMPARATOR
Intervention: Small Volume Nebulizer (SVN)
Number of subjects: 150
Study 14552819 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurine metabolites measurement using HPLC assay in small blood samples from fingertip.
Number of subjects: 0
Study 14552819 — intervention group
Group type: COMPARATOR
Intervention: Measurement of metabolite concentrations in whole blood versus separated RBC.
Number of subjects: 0
Study 14552819 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of 6MP dose on metabolite concentrations.
Number of subjects: 0
Study 14552819 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in metabolite concentrations.
Number of subjects: 0
Study 10832908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 156
Study 10832908 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 156
Study 10832908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 10832908 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 156
Study 9105070 — intervention group
Group type: EXPERIMENTAL
Intervention: Staple
Number of subjects: 72
Study 9105070 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 72
Study 8169485 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of only FDP with regional excision of FDS
Number of subjects: 33
Study 8169485 — intervention group
Group type: COMPARATOR
Intervention: Repair of both FDS and FDP tendons
Number of subjects: 33
Study 3358568 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (alpha-2b, alpha-nl, beta-interferons)
Number of subjects: 79
Study 3358568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 3358568 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 79
Study 31828464 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 211
Study 29546300 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal IDA
Number of subjects: 358
Study 29546300 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal NIDA
Number of subjects: 358
Study 29546300 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepcidin
Number of subjects: 358
Study 24622328 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching hospitals (THs)
Number of subjects: 1491
Study 24622328 — intervention group
Group type: COMPARATOR
Intervention: Municipal hospitals (MHs)
Number of subjects: 1491
Study 24622328 — intervention group
Group type: COMPARATOR
Intervention: Office-based physicians (OBPs)
Number of subjects: 1491
Study 22571900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) plus peginterferon alfa-2a (PegIFNα-2a)
Number of subjects: 90
Study 22571900 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) alone
Number of subjects: 90
Study 22571900 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (PegIFNα-2a) alone
Number of subjects: 90
Study 21062183 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-temperature sensor ingestion at 24 hours before exercise (P1)
Number of subjects: 7
Study 21062183 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-temperature sensor ingestion at 40 minutes before exercise (P2)
Number of subjects: 7
Study 18365136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral epicondyle bandage
Number of subjects: 50
Study 18365136 — intervention group
Group type: COMPARATOR
Intervention: Wrist resting splint holding the wrist in slight dorsiflexion
Number of subjects: 50
Study 15817423 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) interruptions for at least two weeks
Number of subjects: 399
Study 15817423 — intervention group
Group type: COMPARATOR
Intervention: Continued ART
Number of subjects: 399
Study 15817423 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment interruptions (TI)
Number of subjects: 399
Study 14599005 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-effects model, region-of-interest analysis of fMRI study
Number of subjects: 0
Study 10917355 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery with a linear accelerator fitted with a multileaf collimator
Number of subjects: 36
Study 10917355 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged therapy treating the entire volume to 10 Gy twice for AVMs with a volume of more than 25 cc
Number of subjects: 36
Study 7862980 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced CT
Number of subjects: 20
Study 7862980 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 20
Study 1696438 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (20 mg BID for three days)
Number of subjects: 7
Study 1696438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms 20 minutes before the challenge)
Number of subjects: 7
Study 1696438 — intervention group
Group type: COMPARATOR
Intervention: Placebo of astemizole (twice a day for three days)
Number of subjects: 7
Study 7262510 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 29
Study 7262510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31841482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenetic treatment of the digestive tract
Number of subjects: 90
Study 31841482 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional 'clean' territories)
Number of subjects: 90
Study 28211560 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 396
Study 28211560 — intervention group
Group type: COMPARATOR
Intervention: Control (lenalidomide and dexamethasone)
Number of subjects: 396
Study 26033830 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib and celecoxib
Number of subjects: 107
Study 26033830 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib and placebo
Number of subjects: 107
Study 23981904 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g CaHMB consumed twice daily
Number of subjects: 0
Study 23981904 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 0
Study 23981904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20957701 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight suppression (WS)
Number of subjects: 0
Study 19533025 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) and conformal irradiation (dose levels: 66, 72, 78, 84 Gy)
Number of subjects: 0
Study 17276051 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg levosalbutamol
Number of subjects: 30
Study 17276051 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg salbutamol
Number of subjects: 30
Study 17276051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15504763 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pulmonary rehabilitation programme
Number of subjects: 42
Study 15504763 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 11949721 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple correspondence analysis and cluster analysis
Number of subjects: 5103
Study 11949721 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 5103
Study 11949721 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical approach using graphical displays
Number of subjects: 5103
Study 11949721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending hierarchical classification
Number of subjects: 5103
Study 9272426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate combined with 75 micrograms levonorgestrel
Number of subjects: 139
Study 9272426 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg medroxyprogesterone acetate (MPA)
Number of subjects: 139
Study 9272426 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms levonorgestrel
Number of subjects: 139
Study 9272426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg cyproterone acetate
Number of subjects: 139
Study 7519112 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 135
Study 7519112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 2900084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 micrograms.kg‐1
Number of subjects: 32
Study 2900084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.0 micrograms.kg‐1
Number of subjects: 32
Study 2900084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 micrograms.kg‐1
Number of subjects: 32
Study 2900084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30975196 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 500-mg capsule three times daily
Number of subjects: 139
Study 30975196 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50-mg tablet two times daily
Number of subjects: 139
Study 28930769 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target blood alcohol concentration = 0.080%)
Number of subjects: 282
Study 28930769 — intervention group
Group type: COMPARATOR
Intervention: Placebo alcohol (target blood alcohol concentration = 0.000%)
Number of subjects: 282
Study 28930769 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 282
Study 25441978 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseous Resective Surgery (ORS)
Number of subjects: 26
Study 25441978 — intervention group
Group type: COMPARATOR
Intervention: Fibre Retention Osseous Resective Surgery (FibReORS)
Number of subjects: 26
Study 23682927 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from the expert group
Number of subjects: 286
Study 23682927 — intervention group
Group type: COMPARATOR
Intervention: Feedback from the community group
Number of subjects: 286
Study 23682927 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating panel composed of at least 15 raters
Number of subjects: 286
Study 23682927 — intervention group
Group type: EXPERIMENTAL
Intervention: Time 2 ratings
Number of subjects: 286
Study 20936308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild degeneration
Number of subjects: 30
Study 20936308 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate degeneration
Number of subjects: 30
Study 20936308 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe degeneration
Number of subjects: 30
Study 18004709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 19